{"title":"Seroprevalence of <i>Toxoplasma</i>, <i>Rubella</i> and <i>Cytomegalovirus</i> in Women of Fertility Age in Our Region","authors":"İlkay Bahçeci, Esra Karaca, Ömer Faruk Duran, Duygu Aksoy, Yunus Emre İbik, Umut Buğra Kırcı","doi":"10.4274/tpd.galenos.2022.07379","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong><i>Toxoplasma gondii</i> (<i>T. gondii</i>), <i>Rubella</i> and <i>Cytomegalovirus</i> (CMV) infections can cause severe morbidity in the fetus when transmissed during pregnancy. In our study, it was aimed to examine the seropositivity rates for <i>T. gondii</i>, <i>Rubella</i> and CMV infections in women of childbearing age who applied to our hospital.</p><p><strong>Methods: </strong>Anti-<i>Toxoplasma</i> IgG, anti-<i>Toxoplasma</i> IgM, anti-<i>Rubella</i> IgG, anti-<i>Rubella</i> IgM, anti-CMV IgG and anti-CMV were studied in women of childbearing age (18-49 years old) who applied to our hospital's outpatient clinics between January 2018 and December 2020. The tests were performed in our microbiology laboratory using the ELISA method on Architect i2000 (Abbott, USA) and COBAS e601 (Roche, Germany) devices.</p><p><strong>Results: </strong>As a result of the data obtained, the percentages of IgM and IgG positivity for anti-<i>Toxoplasma</i> were calculated as 1.4% and 30.9%, respectively. Anti-<i>Rubella</i> IgM positivity was 0.7%, anti-<i>Rubella</i> IgG positivity was 91%, anti-CMV IgG positivity was 98.8%, and anti-CMV IgM positivity was 2%.</p><p><strong>Conclusion: </strong>Having its own seroprevalence for each region has is important in terms of planning pregnancy screenings. The seropositivity rates in our region are in line with other studies in the country. Since CMV seropositivity is very high in the population and there is no effective treatment or vaccine, screening may not be not necessary. <i>T. gondii</i> and <i>Rubella</i> screenings can be recommended due to the lower immunity rates and the availability of vaccine and treatment options.</p>","PeriodicalId":34974,"journal":{"name":"Turkiye parazitolojii dergisi","volume":"47 1","pages":"11-15"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkiye parazitolojii dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/tpd.galenos.2022.07379","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Toxoplasma gondii (T. gondii), Rubella and Cytomegalovirus (CMV) infections can cause severe morbidity in the fetus when transmissed during pregnancy. In our study, it was aimed to examine the seropositivity rates for T. gondii, Rubella and CMV infections in women of childbearing age who applied to our hospital.
Methods: Anti-Toxoplasma IgG, anti-Toxoplasma IgM, anti-Rubella IgG, anti-Rubella IgM, anti-CMV IgG and anti-CMV were studied in women of childbearing age (18-49 years old) who applied to our hospital's outpatient clinics between January 2018 and December 2020. The tests were performed in our microbiology laboratory using the ELISA method on Architect i2000 (Abbott, USA) and COBAS e601 (Roche, Germany) devices.
Results: As a result of the data obtained, the percentages of IgM and IgG positivity for anti-Toxoplasma were calculated as 1.4% and 30.9%, respectively. Anti-Rubella IgM positivity was 0.7%, anti-Rubella IgG positivity was 91%, anti-CMV IgG positivity was 98.8%, and anti-CMV IgM positivity was 2%.
Conclusion: Having its own seroprevalence for each region has is important in terms of planning pregnancy screenings. The seropositivity rates in our region are in line with other studies in the country. Since CMV seropositivity is very high in the population and there is no effective treatment or vaccine, screening may not be not necessary. T. gondii and Rubella screenings can be recommended due to the lower immunity rates and the availability of vaccine and treatment options.